{"id":6119,"date":"2025-07-23T15:52:04","date_gmt":"2025-07-23T15:52:04","guid":{"rendered":"https:\/\/imas12.es\/en\/?page_id=6119"},"modified":"2025-07-23T16:08:48","modified_gmt":"2025-07-23T16:08:48","slug":"tumor-microenvironment-and-immunotherapy","status":"publish","type":"page","link":"https:\/\/imas12.es\/en\/research\/cancer\/tumor-microenvironment-and-immunotherapy\/","title":{"rendered":"Tumor Microenvironment and Immunotherapy"},"content":{"rendered":"<p style=\"text-align: justify\" data-start=\"53\" data-end=\"299\">Our research group is strongly focused on clinical application. The group conducts translational studies using a reverse design approach, aiming to develop new biomarkers and rational, personalized therapeutic strategies for lung cancer patients.<\/p>\n<p style=\"text-align: justify\" data-start=\"301\" data-end=\"329\"><strong data-start=\"301\" data-end=\"329\">PRIORITY RESEARCH LINES:<\/strong><\/p>\n<ul data-start=\"331\" data-end=\"751\">\n<li style=\"text-align: justify\" data-start=\"331\" data-end=\"457\">\n<p data-start=\"333\" data-end=\"457\">Discover and validate new mechanisms of sensitivity and resistance to immunotherapy and targeted therapies in lung cancer.<\/p>\n<\/li>\n<li style=\"text-align: justify\" data-start=\"458\" data-end=\"520\">\n<p data-start=\"460\" data-end=\"520\">Identify new therapeutic targets for lung cancer patients.<\/p>\n<\/li>\n<li style=\"text-align: justify\" data-start=\"521\" data-end=\"586\">\n<p data-start=\"523\" data-end=\"586\">Develop robust and clinically scalable predictive biomarkers.<\/p>\n<\/li>\n<li data-start=\"587\" data-end=\"751\">\n<p style=\"text-align: justify\" data-start=\"589\" data-end=\"751\">Design and conduct early-phase (Phase I\u2013II) and late-phase (Phase III) clinical trials with novel immunotherapies and targeted therapies for lung cancer patients.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Our research group is strongly focused on clinical application. The group conducts translational studies using a reverse design approach, aiming to develop new biomarkers and rational, personalized therapeutic strategies for lung cancer patients. PRIORITY RESEARCH LINES: Discover and validate new&#8230;<\/p>\n","protected":false},"author":8,"featured_media":0,"parent":24,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"research-group.php","meta":{"footnotes":""},"class_list":["post-6119","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/pages\/6119","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/comments?post=6119"}],"version-history":[{"count":3,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/pages\/6119\/revisions"}],"predecessor-version":[{"id":6135,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/pages\/6119\/revisions\/6135"}],"up":[{"embeddable":true,"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/pages\/24"}],"wp:attachment":[{"href":"https:\/\/imas12.es\/en\/wp-json\/wp\/v2\/media?parent=6119"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}